NextCure (NASDAQ:NXTC) Stock Dropped to “Sell” by Wall Street Zen

Wall Street Zen lowered shares of NextCure (NASDAQ:NXTC) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other equities analysts have also recently weighed in on NXTC. HC Wainwright restated a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Weiss Ratings raised shares of NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.00.

NextCure Trading Up 2.7%

NASDAQ NXTC traded up $0.17 during mid-day trading on Friday, hitting $6.40. The company’s stock had a trading volume of 37,697 shares, compared to its average volume of 58,816. The company’s 50 day simple moving average is $5.98 and its 200 day simple moving average is $7.55. NextCure has a twelve month low of $1.55 and a twelve month high of $15.74. The firm has a market capitalization of $29.31 million, a price-to-earnings ratio of -0.95 and a beta of 1.22.

NextCure (NASDAQ:NXTC) last posted its earnings results on Tuesday, November 10th. The company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.39).

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 5,626 shares of the stock in a transaction on Friday, October 23rd. The shares were purchased at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the purchase, the insider directly owned 728,045 shares in the company, valued at $3,516,457.35. This represents a 0.78% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders acquired 15,537 shares of company stock valued at $77,603 in the last 90 days. Insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On NextCure

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC boosted its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the period. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company researches immunomedicines designed to influence how immune cells recognize and respond to tumors; it does not market approved commercial products. Its discovery work has included antibody-based and small-molecule candidates aimed at immune-related targets such as Siglec-15, LAIR-1 and CBL-B. NextCure has used its FIND-IT platform to identify and investigate potential therapeutic targets and drug candidates.